Key result
MEK-ERK1/2 signaling regulates cardiac hypertrophy, where its activation promotes concentric hypertrophy and its loss leads to eccentric hypertrophy and cardiac dilatation.
This review highlights that ERK1/2 signaling is crucial for preventing maladaptive eccentric cardiac growth, though its role in concentric hypertrophy is complex and context-dependent.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for ERK1/2-targeted therapies in hypertrophy subtypes; leaves open clinical translation pending human validation.
Cardiac hypertrophy results from increased mechanical load on the heart and through the actions of local and systemic neuro-humoral factors, cytokines and growth factors. These mechanical and neuroendocrine effectors act through stretch, G protein-coupled receptors and tyrosine kinases to induce the activation of a myriad of intracellular signaling pathways including the extracellular signal-regulated kinases 1/2 (ERK1/2). Since most stimuli that provoke myocardial hypertrophy also elicit an acute phosphorylation of the threonine-glutamate-tyrosine (TEY) motif within the activation loops of ERK1 and ERK2 kinases, resulting in their activation, ERKs have long been considered promotors of cardiac hypertrophy. Several mouse models were generated in order to directly understand the causal role of ERK1/2 activation in the heart. These models include direct manipulation of ERK1/2 such as overexpression, mutagenesis or knockout models, manipulations of upstream kinases such as MEK1 and manipulations of the phosphatases that dephosphorylate ERK1/2 such as DUSP6. The emerging understanding from these studies, as will be discussed here, is more complex than originally considered. While there is little doubt that ERK1/2 activation or the lack of it modulates the hypertrophic process or the type of hypertrophy that develops, it appears that not all ERK1/2 activation events are the same. While much has been learned, some questions remain regarding the exact role of ERK1/2 in the heart, the upstream events that result in ERK1/2 activation and the downstream effector in hypertrophy.
No takes yet. Share an insight, caveat, or question.
Mutlak et al. (2015) conducted a review in Cardiac hypertrophy. ERK1/2 signaling modulation was evaluated. MEK-ERK1/2 signaling regulates cardiac hypertrophy, where its activation promotes concentric hypertrophy and its loss leads to eccentric hypertrophy and cardiac dilatation.
Synapse has enriched 10 related papers. Consider them for comparative context: